{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:37:07Z","timestamp":1792510627426,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.medcli.2023.06.006","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T15:11:43Z","timestamp":1691421103000},"page":"389-396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Fibrosis qu\u00edstica: epidemiolog\u00eda, cl\u00ednica, diagn\u00f3stico y tratamiento"],"prefix":"10.1016","volume":"161","author":[{"given":"Layla","family":"Diab C\u00e1ceres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Zamarr\u00f3n de Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2023.06.006_bib0300","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.medcli.2023.06.006_bib0305","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/MCP.0b013e32833e9e27","article-title":"Emerging issues in cystic fibrosis newborn screening","volume":"16","author":"Castellani","year":"2010","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.medcli.2023.06.006_bib0310","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/MCP.0000000000000520","article-title":"Cystic fibrosis survival: the changing epidemiology","volume":"24","author":"Corriveau","year":"2018","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.medcli.2023.06.006_bib0315","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1091\/mbc.e14-04-0935","article-title":"From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations","volume":"27","author":"Veit","year":"2016","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.medcli.2023.06.006_bib0320","doi-asserted-by":"crossref","first-page":"251.e1","DOI":"10.1016\/j.anpedi.2018.11.009","article-title":"Protocolo de seguimiento de pacientes con fibrosis qu\u00edstica diagnosticados por cribado neonatal","volume":"90","author":"Gartner","year":"2019","journal-title":"An Pediatr\u00eda"},{"key":"10.1016\/j.medcli.2023.06.006_bib0325","first-page":"2022","author":"Orenti","year":"2020","journal-title":"ECFSPR Annual Report"},{"key":"10.1016\/j.medcli.2023.06.006_bib0330","unstructured":"Spanish Cystic Fibrosis Registry: Report 2019, Spanish Cystic Fibrosis Society Registry Group. 2022."},{"key":"10.1016\/j.medcli.2023.06.006_bib0335","unstructured":"Welcome to CFTR2 | CFTR2 s.\u00a0f. [https:\/\/cftr2.org\/]."},{"key":"10.1016\/j.medcli.2023.06.006_bib0340","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.medcli.2023.06.006_bib0345","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1164\/rccm.200403-381WS","article-title":"Macromolecular Interactions and Ion Transport in Cystic Fibrosis","volume":"170","author":"Guggino","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.medcli.2023.06.006_bib0350","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"10.1016\/j.medcli.2023.06.006_bib0355","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jpeds.2016.09.065","article-title":"Diagnosis of Cystic Fibrosis in Screened Populations","volume":"181S","author":"Farrell","year":"2017","journal-title":"J Pediatr"},{"key":"10.1016\/j.medcli.2023.06.006_bib0360","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jcf.2019.04.010","article-title":"Inconclusive diagnosis after a positive newborn bloodspot screening result for cystic fibrosis; clarification of the harmonised international definition","volume":"18","author":"Southern","year":"2019","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"10.1016\/j.medcli.2023.06.006_bib0365","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0022-3476(98)70344-0","article-title":"The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel","volume":"132","author":"Rosenstein","year":"1998","journal-title":"J Pediatr"},{"key":"10.1016\/j.medcli.2023.06.006_bib0370","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.arbres.2017.07.015","article-title":"Spanish Guidelines on the Evaluation and Diagnosis of Bronchiectasis in Adults","volume":"54","author":"Mart\u00ednez-Garc\u00eda","year":"2018","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.medcli.2023.06.006_bib0375","first-page":"6","article-title":"Inflammation: a two-edged sword--the model of bronchiectasis","volume":"147","author":"Cole","year":"1986","journal-title":"Eur J Respir Dis Suppl"},{"key":"10.1016\/j.medcli.2023.06.006_bib0380","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jcf.2020.02.015","article-title":"Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease","volume":"19","author":"Kapnadak","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.medcli.2023.06.006_bib0385","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2023.06.006_bib0390","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2023.06.006_bib0395","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/oxfordjournals.aje.a008664","article-title":"Determinants of mortality from cystic fibrosis in Canada, 1970-1989","volume":"143","author":"Corey","year":"1996","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.medcli.2023.06.006_bib0400","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s00330-020-07095-y","article-title":"Predictive value of the modified Bhalla score for assessment of pulmonary exacerbations in adults with cystic fibrosis","volume":"31","author":"Diab-C\u00e1ceres","year":"2021","journal-title":"Eur Radiol"},{"key":"10.1016\/j.medcli.2023.06.006_bib0405","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1007\/s00330-020-06759-z","article-title":"Predictive value of computed tomography scoring systems evolution in adults with cystic fibrosis","volume":"30","author":"Zorzo","year":"2020","journal-title":"Eur Radiol"},{"key":"10.1016\/j.medcli.2023.06.006_bib0410","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1378\/chest.130.5.1424","article-title":"Pulmonary abnormalities on high-resolution CT demonstrate more rapid decline than FEV1 in adults with cystic fibrosis","volume":"130","author":"Judge","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.medcli.2023.06.006_bib0415","doi-asserted-by":"crossref","first-page":"606","DOI":"10.4187\/aarc0493","article-title":"Monitoring respiratory disease severity in cystic fibrosis","volume":"54","author":"Davies","year":"2009","journal-title":"Respir Care"},{"key":"10.1016\/j.medcli.2023.06.006_bib0420","doi-asserted-by":"crossref","first-page":"87","DOI":"10.21037\/atm.2016.03.08","article-title":"Chest CT abnormalities and quality of life: relationship in adult cystic fibrosis","volume":"4","author":"Kilcoyne","year":"2016","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.medcli.2023.06.006_bib0425","first-page":"10","article-title":"Ten years of chest MRI for patients with cystic fibrosis: Translation from the bench to clinical routine","volume":"59","author":"Leutz-Schmidt","year":"2019","journal-title":"Radiol"},{"key":"10.1016\/j.medcli.2023.06.006_bib0430","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jhep.2021.09.042","article-title":"Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies","volume":"76","author":"Dana","year":"2022","journal-title":"J Hepatol"},{"issue":"Suppl 47","key":"10.1016\/j.medcli.2023.06.006_bib0435","first-page":"29","article-title":"Male infertility and cystic fibrosis","volume":"100","author":"Rutherford","year":"2007","journal-title":"J R Soc Med"},{"key":"10.1016\/j.medcli.2023.06.006_bib0440","first-page":"CD002768","article-title":"Physical exercise training for cystic fibrosis","volume":"2017","author":"Radtke","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.medcli.2023.06.006_bib0445","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3390\/antibiotics10050486","article-title":"Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review","volume":"10","author":"Gir\u00f3n Moreno","year":"2021","journal-title":"Antibiotics"},{"key":"10.1016\/j.medcli.2023.06.006_bib0450","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/MCP.0b013e32834b6af4","article-title":"The role of exercise in maintaining health in cystic fibrosis","volume":"17","author":"Dwyer","year":"2011","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.medcli.2023.06.006_bib0455","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.jcf.2020.07.009","article-title":"A Four Week Trial of Hypertonic Saline in Children with Mild Cystic Fibrosis Lung Disease: Effect on Mucociliary Clearance and Clinical Outcomes","volume":"19","author":"Donaldson","year":"2020","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"10.1016\/j.medcli.2023.06.006_bib0460","series-title":"Tratado de Fibrosis Qu\u00edstica","author":"Salcedo Posadas","year":"2012"},{"key":"10.1016\/j.medcli.2023.06.006_bib0465","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S2213-2600(19)30187-0","article-title":"Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"7","author":"Ratjen","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.medcli.2023.06.006_bib0470","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa043900","article-title":"A Controlled Trial of Long-Term Inhaled Hypertonic Saline in Patients with Cystic Fibrosis","author":"Elkins","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2023.06.006_bib0475","doi-asserted-by":"crossref","unstructured":"Wark P, McDonald VM, Jones AP. Nebulised hypertonic saline for cystic fibrosis. En: The Cochrane Collaboration, editor. Cochrane Database Syst. Rev., Chichester, UK: John Wiley & Sons, Ltd; 2005, p. CD001506.pub2.","DOI":"10.1002\/14651858.CD001506.pub2"},{"key":"10.1016\/j.medcli.2023.06.006_bib0480","first-page":"CD001127","article-title":"Dornase alfa for cystic fibrosis","volume":"2021","author":"Yang","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.medcli.2023.06.006_bib0485","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group","volume":"331","author":"Fuchs","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2023.06.006_bib0490","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s10096-015-2347-4","article-title":"Azithromycin use in patients with cystic fibrosis","volume":"34","author":"Principi","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.medcli.2023.06.006_bib0495","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1378\/chest.09-0132","article-title":"Respiratory Microbiology of Patients With Cystic Fibrosis in the United States, 1995 to 2005","volume":"136","author":"Razvi","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.medcli.2023.06.006_bib0500","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1136\/thoraxjnl-2013-203204","article-title":"Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications","volume":"68","author":"Cohen-Cymberknoh","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.medcli.2023.06.006_bib0505","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002203.pub4","article-title":"Macrolide antibiotics for cystic fibrosis","author":"Southern","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.medcli.2023.06.006_bib0510","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1164\/rccm.201911-2234ED","article-title":"Evaluating Long-Term Benefits of Chronic Azithromycin. Furthering Our Quest for Precision Medicine","volume":"201","author":"Saiman","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.medcli.2023.06.006_bib0515","first-page":"CD006682","article-title":"Duration of intravenous antibiotic therapy in people with cystic fibrosis","volume":"2019","author":"Abbott","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.medcli.2023.06.006_bib0520","first-page":"10","article-title":"A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2023.06.006_bib0525","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-2600(15)00201-5","article-title":"Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial","volume":"3","author":"Moss","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.medcli.2023.06.006_bib0530","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jcf.2014.09.005","article-title":"Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation","volume":"13","author":"De Boeck","year":"2014","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"key":"10.1016\/j.medcli.2023.06.006_bib0535","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1164\/rccm.201301-0153OC","article-title":"Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation","volume":"187","author":"Davies","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.medcli.2023.06.006_bib0540","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S2213-2600(14)70218-8","article-title":"Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)","volume":"2","author":"McKone","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.medcli.2023.06.006_bib0545","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study","volume":"4","author":"Davies","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.medcli.2023.06.006_bib0550","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","article-title":"Ivacaftor treatment of cystic fibrosis in children aged 12 to<24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study","volume":"6","author":"Rosenfeld","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.medcli.2023.06.006_bib0555","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S2213-2600(16)30121-7","article-title":"Efficacy and safety of lumacaftor\/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup","volume":"4","author":"Elborn","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.medcli.2023.06.006_bib0560","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(16)30427-1","article-title":"Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study","volume":"5","author":"Konstan","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.medcli.2023.06.006_bib0565","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S2213-2600(18)30460-0","article-title":"Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study","volume":"7","author":"McNamara","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.medcli.2023.06.006_bib0570","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2023.06.006_bib0575","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis","volume":"377","author":"Rowe","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2023.06.006_bib0580","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"The Lancet"},{"key":"10.1016\/j.medcli.2023.06.006_bib0585","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2023.06.006_bib0590","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2014.06.014","article-title":"A consensus document for the selection of lung transplant candidates: 2014\u2014An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation","volume":"34","author":"Weill","year":"2015","journal-title":"J Heart Lung Transplant"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775323003627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775323003627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:56:57Z","timestamp":1758419817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775323003627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":59,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0025775323003627"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2023.06.006","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fibrosis qu\u00edstica: epidemiolog\u00eda, cl\u00ednica, diagn\u00f3stico y tratamiento","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2023.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}